Kenvue Inc.
- Industria
- Household & Personal Care
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 4 de mayo de 2023
- Empleados
- 21.780
- Sitio web
- www.kenvue.com
Rango de valoración compuesto · conservador $10–$13 / razonable $16–$20 / optimista $22–$26. A $18.12, Dentro del rango de valor intrínseco razonable.
Al publicar $17.69 (28 de mayo de 2026)
Aún no hay análisis sobre este valor en tu idioma.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Historia
PróximamenteEsta sección se está completando; vuelve pronto.
Posición en el sector
PróximamenteEsta sección se está completando; vuelve pronto.
